PharmacoEconomics

Formulary Restriction of Selective Serotonin Reuptake Inhibitors for Depression: Potential Pitfalls
pp. 973-982(10)
Authors: Hensley P.L.; Nurnberg H.G.

Which Antifungal Agent for Onychomycosis?: A Pharmacoeconomic Analysis
pp. 983-1002(20)
Authors: Joish V.N.; Armstrong E.P.

Barrett's Oesophagus: A Review of Costs of the Illness
pp. 1003-1011(9)
Authors: Arguedas M.R.; Eloubeidi M.A.

Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson's Disease: Impact of Motor Fluctuations and Dyskinesias
pp. 1013-1038(26)
Authors: Dodel R.C.; Berger K.; Oertel W.H.

Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis: Ontario Ministry of Health Perspective
pp. 1039-1049(11)
Authors: Marshall J.K.; Pellissier J.M.; Attard C.L.; Kong S.X.; Marentette M.A.

A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis
pp. 1051-1064(14)
Authors: Nuijten M.J.C.; Engelfriet P.; Duijn K.; Bruijn G.; Wierz D.; Koopmanschap M.